United Therapeutics Corporation entered into an accelerated share repurchase agreement with Citibank to repurchase approximately $477.6 million of its common stock, utilizing the remainder of its previously announced $2 billion authorization. The company will make an upfront payment on or around September 10, 2026, and receive an initial delivery of approximately 719,376 shares, representing roughly 75% of the anticipated total repurchase based on the closing price on September 8, 2026. Final settlement is expected in the fourth quarter of 2026, with the exact share count determined by the average daily volume-weighted average price during the agreement term. This transaction brings total shareholder returns to approximately $4 billion over the past 2.5 years. United Therapeutics operates in the biotechnology industry, focusing on discovering cures and treatments for rare diseases such as pulmonary arterial hypertension.

United Therapeutics Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total revenues decreased two percent year-over-year to $783.3 million from $798.6 million in the prior year period. Net income increased eight percent to $333.0 million, or $7.27 per diluted share, compared to $309.5 million and $6.41 per diluted share previously. The company announced the submission of new drug applications for ralinepag tablets in pulmonary arterial hypertension and Nebulized Tyvaso in idiopathic fibrosis. Additionally, United Therapeutics disclosed that it repurchased 2,759,343 shares under accelerated share repurchase agreements initiated in March 2026, with $500 million remaining available under the board-approved program.

United Therapeutics Corporation increased its Board of Directors to 13 members following the appointment of Victor Dzau, M.D., effective July 22, 2026. Dr. Dzau, formerly President of the National Academy of Medicine, received 380 restricted stock units and 1,190 stock options as an initial grant, plus pro-rata grants of 350 restricted stock units and 1,110 stock options for the remainder of the 2026-2027 service year. The appointment is part of a board refreshment effort. United Therapeutics is a biotechnology company focused on developing treatments for rare diseases and organ alternatives.

At its 2026 Annual Meeting of Shareholders held on June 26, 2026, United Therapeutics Corporation shareholders approved the 2026 Stock Incentive Plan. This new plan, effective immediately, allows for the issuance of an aggregate number of common stock shares equal to the sum of 2,413,730 shares remaining from the prior 2015 plan plus 1,500,000 new shares, alongside shares from canceled or forfeited awards. Additionally, shareholders elected twelve directors, approved an advisory resolution regarding executive compensation, and ratified Ernst & Young LLP as the independent registered public accounting firm for 2026. United Therapeutics Corporation is a biotechnology company focused on developing therapies for serious diseases.